Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

220 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An inflatable balloon catheter and liquid 125I radiation source (GliaSite Radiation Therapy System) for treatment of recurrent malignant glioma: multicenter safety and feasibility trial.
Tatter SB, Shaw EG, Rosenblum ML, Karvelis KC, Kleinberg L, Weingart J, Olson JJ, Crocker IR, Brem S, Pearlman JL, Fisher JD, Carson K, Grossman SA; New Approaches to Brain Tumor Therapy Central Nervous System Consortium. Tatter SB, et al. J Neurosurg. 2003 Aug;99(2):297-303. doi: 10.3171/jns.2003.99.2.0297. J Neurosurg. 2003. PMID: 12924704
A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting.
Chiocca EA, Abbed KM, Tatter S, Louis DN, Hochberg FH, Barker F, Kracher J, Grossman SA, Fisher JD, Carson K, Rosenblum M, Mikkelsen T, Olson J, Markert J, Rosenfeld S, Nabors LB, Brem S, Phuphanich S, Freeman S, Kaplan R, Zwiebel J. Chiocca EA, et al. Mol Ther. 2004 Nov;10(5):958-66. doi: 10.1016/j.ymthe.2004.07.021. Mol Ther. 2004. PMID: 15509513 Free article. Clinical Trial.
Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas.
Grossman SA, Alavi JB, Supko JG, Carson KA, Priet R, Dorr FA, Grundy JS, Holmlund JT. Grossman SA, et al. Among authors: carson ka. Neuro Oncol. 2005 Jan;7(1):32-40. doi: 10.1215/S1152851703000353. Neuro Oncol. 2005. PMID: 15701280 Free PMC article. Clinical Trial.
220 results